Secondary endpoints include safety, pharmacokinetics, improvement in bone marrow fibrosis, and change in total symptom score (modified Myelofibrosis Symptom Assessment Form v 2.0), JAK2 V617F allele burden, cytokine levels, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30. Here, JAK2 is linked to primary myelofibrosis.